LCG
CRSP icon

Lisanti Capital Growth’s CRISPR Therapeutics CRSP Stock Holding History

Lisanti Capital Growth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,560
Closed -$851K – 141
2020
Q4 		$851K Buy
+5,560
New +$657K 0.12% 124
2020
Q2 		– Sell
-16,690
Closed -$708K – 122
2020
Q1 		$708K Buy
16,690
+7,175
+75% +$370K 0.23% 98
2019
Q4 		$580K Buy
+9,515
New +$520K 0.15% 110

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Lisanti Capital Growth's CRSP Position: Q1 2021 in Review

Lisanti Capital Growth sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 5,560 shares — an estimated $851K sold.

Lisanti Capital Growth first reported a position in CRSP in Q4 2019 and held it in 3 quarters. The position peaked at $851K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • Lisanti Capital Growth reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Lisanti Capital Growth sold 5,560 CRISPR Therapeutics shares in Q1 2021, an estimated $851K.
  • Lisanti Capital Growth first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 3 quarters.
  • Lisanti Capital Growth's CRISPR Therapeutics position peaked at $851K in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Lisanti Capital Growth's 13F filing for Q1 2021, filed 12 May 2021.